share_log

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating Da-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating Da-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals | 8-K：NeuroBo Pharmaceuticals報告了DA-1241與西格列汀聯合使用的臨床前安全性數據陽性，並開放了其評估DA-1241治療麻疹的 2a 期臨床試驗第2部分的註冊
SEC announcement ·  01/18 13:00

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。